KR20180064540A - 암 치료를 위한 mdm2 억제제의 투여 요법 - Google Patents

암 치료를 위한 mdm2 억제제의 투여 요법 Download PDF

Info

Publication number
KR20180064540A
KR20180064540A KR1020187014440A KR20187014440A KR20180064540A KR 20180064540 A KR20180064540 A KR 20180064540A KR 1020187014440 A KR1020187014440 A KR 1020187014440A KR 20187014440 A KR20187014440 A KR 20187014440A KR 20180064540 A KR20180064540 A KR 20180064540A
Authority
KR
South Korea
Prior art keywords
days
compound
salt
administered
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187014440A
Other languages
English (en)
Korean (ko)
Inventor
응아이-치우 아치 체
성리 카이
Original Assignee
다이이찌 산쿄 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이이찌 산쿄 가부시키가이샤 filed Critical 다이이찌 산쿄 가부시키가이샤
Publication of KR20180064540A publication Critical patent/KR20180064540A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020187014440A 2015-10-23 2016-10-21 암 치료를 위한 mdm2 억제제의 투여 요법 Ceased KR20180064540A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562245632P 2015-10-23 2015-10-23
US62/245,632 2015-10-23
PCT/JP2016/081975 WO2017069289A1 (en) 2015-10-23 2016-10-21 Dosage regimen of mdm2 inhibitor for treating cancers

Publications (1)

Publication Number Publication Date
KR20180064540A true KR20180064540A (ko) 2018-06-14

Family

ID=57349101

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187014440A Ceased KR20180064540A (ko) 2015-10-23 2016-10-21 암 치료를 위한 mdm2 억제제의 투여 요법

Country Status (8)

Country Link
US (3) US20180296547A1 (enExample)
EP (1) EP3364972A1 (enExample)
JP (4) JP6855472B2 (enExample)
KR (1) KR20180064540A (enExample)
CN (2) CN113521069A (enExample)
HK (1) HK1253098A1 (enExample)
TW (3) TWI806822B (enExample)
WO (1) WO2017069289A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10409015B1 (en) 2015-12-15 2019-09-10 Optomind Inc. Optical receiving device including focusing lens and reflector mounted to housing body and collimating lens mounted to housing cover

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI697329B (zh) * 2015-04-13 2020-07-01 日商第一三共股份有限公司 血液癌症治療用之醫藥及其用途
HK1253098A1 (zh) * 2015-10-23 2019-06-06 Daiichi Sankyo Company, Limited 用於治疗癌症的mdm2抑制剂的给药方案
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
WO2023016977A1 (en) * 2021-08-09 2023-02-16 Boehringer Ingelheim International Gmbh Oral composition comprising a mdm2-antagonist for cancer therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE470665T1 (de) * 2006-03-22 2010-06-15 Janssen Pharmaceutica Nv Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53
EP2059236A2 (en) * 2006-08-21 2009-05-20 Synta Pharmaceuticals Corporation Combination with bis(thiohydrazide amides) for treating cancer
JP5438008B2 (ja) * 2007-09-21 2014-03-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ＭＤＭ２とｐ５３の間の相互作用の阻害剤
TR201807311T4 (tr) * 2011-03-10 2018-06-21 Daiichi Sankyo Co Ltd Dispiropirolidin derivesi.
WO2013101436A1 (en) * 2011-12-07 2013-07-04 Duke University Methods of identifying and using mdm2 inhibitors
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
JP5958208B2 (ja) * 2012-09-10 2016-07-27 凸版印刷株式会社 包装袋
BR112016004593B1 (pt) * 2013-09-04 2022-12-06 Daiichi Sankyo Company, Limited Métodos para reagir um composto, para hidrolisar um composto ou um sal do mesmo, para produzir um composto e para preparar um composto
EP3094746A1 (en) * 2014-01-14 2016-11-23 Daiichi Sankyo Company, Limited Gene signatures associated with sensitivity to mdm2 inhibitors
CN107427501B (zh) * 2015-02-20 2023-12-01 第一三共株式会社 通过联合使用治疗癌症的方法
TWI697329B (zh) * 2015-04-13 2020-07-01 日商第一三共股份有限公司 血液癌症治療用之醫藥及其用途
HK1253098A1 (zh) * 2015-10-23 2019-06-06 Daiichi Sankyo Company, Limited 用於治疗癌症的mdm2抑制剂的给药方案

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10409015B1 (en) 2015-12-15 2019-09-10 Optomind Inc. Optical receiving device including focusing lens and reflector mounted to housing body and collimating lens mounted to housing cover

Also Published As

Publication number Publication date
JP2024164122A (ja) 2024-11-26
TW201722427A (zh) 2017-07-01
JP6855472B2 (ja) 2021-04-07
WO2017069289A1 (en) 2017-04-27
US20180296547A1 (en) 2018-10-18
CN113521069A (zh) 2021-10-22
US20220071975A1 (en) 2022-03-10
TWI806822B (zh) 2023-07-01
JP7192011B2 (ja) 2022-12-19
HK1253098A1 (zh) 2019-06-06
US11058673B2 (en) 2021-07-13
CN108135892A (zh) 2018-06-08
TW202332444A (zh) 2023-08-16
EP3364972A1 (en) 2018-08-29
TW202515561A (zh) 2025-04-16
JP2021098750A (ja) 2021-07-01
US20190201386A1 (en) 2019-07-04
JP2023025214A (ja) 2023-02-21
JP2018531273A (ja) 2018-10-25

Similar Documents

Publication Publication Date Title
JP7192011B2 (ja) がんを治療するためのｍｄｍ２阻害剤の投与計画
AU2019240572B2 (en) Compositions and methods for treating cancers associated with ETBR activation
HK1221408A1 (zh) 用於治疗成胶质细胞瘤的组合疗法
JP6995058B2 (ja) （１ｓ，４ｓ）－４－（２－（（（３ｓ，４ｒ）－３－フルオロテトラヒドロ－２ｈ－ピラン－４－イル）アミノ）－８－（（２，４，６－トリクロロフェニル）アミノ）－９ｈ－プリン－９－イル）－１－メチルクロロヘキサン－１－カルボキサミドの固体形態及びその使用方法
JP2020515609A (ja) がんの治療のための抗ｐｄ−ｌ１抗体およびｄｎａ−ｐｋインヒビターの併用
JP2018531273A6 (ja) がんを治療するためのｍｄｍ２阻害剤の投与計画
TW201343178A (zh) 用於治療卵巢癌之組合療法
EP3697767B1 (en) Compounds and methods for treating cancer
EP3284466A1 (en) Treatment method combining mdm2 inhibitor and btk inhibitor
EP4010002A1 (en) Novel therapeutic use
KR20210010524A (ko) 샘낭암종을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조성물
TR201908138T4 (tr) Bir anti-her2 antikoru ilaç konjügatı ve bir bcl-2 inhibitörü ile kombinasyon terapisi.
KR102823786B1 (ko) 조합 의약으로서 사용되는 ezh1/2 이중 저해제를 함유하는 의약 조성물
CN119894514A (zh) 药物组合物及其用途
HK40031775B (en) Compounds and methods for treating cancer
HK40031775A (en) Compounds and methods for treating cancer
CN119818513A (zh) 治疗儿科患者的癌症的方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000